Up-to-date prescription details regarding Mipomersen Injection are provided here. Understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, ...

Review the side-effects of Mipomersen Injection as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

Although the concept of using synthetic oligonucleotides to modulate RNA function was described as early as 1978, 1 its realization in the form of drugs approved by the Food and Drug Administration ...

Homozygous familial hypercholesterolemia is a rare genetic condition that is often characterized by an increased risk of premature cardiovascular (CV) events and cardiac death. Lomitapide decreases ...

Homozygous familial hypercholesterolemia is characterized by profound genetic deficiencies in the low-density lipoprotein (LDL) receptor pathway; patients with the condition who are not receiving ...

KYNAMRO (mipomersen sodium) 200mg/mL injection The Food and Drug Administration (FDA) announced changes to the Kynamro (mipomersen sodium; Genzyme) Approved Risk Evaluation and Mitigation Strategies ...

Led by Dr P Barton Duell (Oregon Health and Science University, Portland), the researchers analyzed data from three phase 3 randomized placebo-controlled trials of 104 patients with homozygous, ...

Please provide your email address to receive an email when new articles are posted on . Mipomersen effectively and safely reduced all atherosclerotic lipoproteins associated with familial ...

Please provide your email address to receive an email when new articles are posted on . Mipomersen significantly decreased levels of LDL cholesterol, apolipoprotein B and lipoprotein(a) in patients ...

The FDA has approved a new drug that not only treats a rare genetic disease that causes extremely high cholesterol levels, but does so using first-of-its-kind technology that has been enhanced over ...

The FDA said today that it had granted approval to the novel cholesterol-lowering drug mipomersen sodium for use as an adjunct to diet and drug therapy in patients with homozygous hypercholesterolemia ...

BETHESDA, Maryland — The US FDA has approved mipomersen sodium (Kynamro, Genzyme, Cambridge MA), a once-weekly subcutaneous injection, as an adjunct to maximally tolerated lipid-lowering medications ...